NPPB and hydrops fetalis: Furthermore, during a follow-up period lasting 12 weeks after discharge, the levels of NT-proBNP and the risk of endpoint events such as cardiovascular death and rehospitalization for HF were reduced by an average of 30% in patients with HF who continued taking ARNI compared to those who switched to enalapril (26).